Episode 125: AML Series, Pt 11 - Treatment of patients unfit for intensive therapy
The Fellow on Call: The Heme/Onc Podcast
Advancements in AML Treatment for Fragile Patients
This chapter evaluates the progress in treating acute myeloid leukemia (AML) for patients unfit for intensive therapies, focusing on the use of azacitidine and venetoclax. The discussion highlights significant clinical trials, including Viali-A and LACEWING, demonstrating improved response rates and survival outcomes while addressing the challenges of myelosuppression management. Additionally, the speakers emphasize the importance of trial data in informing treatment strategies and the implications of cost-effectiveness in clinical practice.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
